Opus Genetics corrects 3-month BCVA data in OPGx-BEST1 Cohort 1; mixed outcomes across 5 patients

Opus Genetics, Inc.

Corrected 3-month BCVA changes: 101-101 treated eye +12 letters, fellow eye +4 letters.
101-104 treated +1 letter, fellow -7; 102-101 treated -10, fellow -8 letters.
102-102 treated +2 letters, fellow -5; 101-106 treated +6, fellow +2 letters.
Revision fixes immaterial logMAR-to-ETDRS translation error on Slide 15; high-res microperimetry grids added to appendix.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.